Meglumine antimoniate
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
ATC code | |
Identifiers | |
| |
Synonyms | meglumine antimonate |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
NIAID ChemDB | |
ECHA InfoCard | 100.004.645 |
Chemical and physical data | |
Formula | Variable |
Molar mass | Variable |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Meglumine antimoniate is a medicine used to treat leishmaniasis.[1] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.[1] It is given by injection into a muscle or into the area infected.[1]
Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems.[1] It should not be used in people with significant heart, liver, or kidney problems.[1] It is not recommended during breastfeeding.[1] It belongs to a group of medications known as the pentavalent antimonials.[1]
Meglumine antimoniate came into medical use in 1946.[2] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] The wholesale cost in the developing world is about 4.32 USD per vial as of 2014.[4] It is available in Southern Europe and Latin America but not the United States.[5][6]
Society and culture
It is manufactured by Aventis[7] and sold as Glucantime in France, and Glucantim in Italy.
See also
References
- 1 2 3 4 5 6 7 WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 183. ISBN 9789241547659. Retrieved 8 December 2016.
- ↑ Sneader, Walter (2005). Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520.
- ↑ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
- ↑ "Meglumine Antimonate". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- ↑ Bope, Edward T.; Kellerman, Rick D.; Rakel, Robert E. (2010). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 143773572X.
- ↑ Gorbach, Sherwood L.; Bartlett, John G.; Blacklow, Neil R. (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717.
- ↑ Aventis press release, 15 April 2005. (in German)